20:45 , Feb 10, 2017 |  BC Week In Review  |  Company News

GenomeDx, Astellas deal

GenomeDx and Astellas partnered to identify prostate cancer patients undergoing active surveillance who may benefit from treatment with the pharma's Xtandi enzalutamide. Astellas will provide tumor samples from its ongoing Phase II ENACT trial, which...
08:00 , Feb 9, 2015 |  BC Week In Review  |  Company News

GenomeDx Biosciences sales and marketing update

GenomeDx said Medicare administrative contractor Palmetto GBA issued a positive coverage policy through its MolDX Program for GenomeDx’s Decipher Prostate Cancer Classifier to measure the risk of developing metastatic prostate cancer in men who have...
07:00 , Oct 20, 2014 |  BC Week In Review  |  Clinical News

Decipher Prostate Cancer Classifier regulatory update

GenomeDx said Medicare administrative contractor Palmetto GBA issued a draft local coverage determination (LCD) recommending coverage for GenomeDx's Decipher Prostate Cancer Classifier. The draft recommends the laboratory-developed test (LDT) to measure the risk of developing...
07:00 , Jun 23, 2014 |  BC Week In Review  |  Company News

GenomeDx Biosciences Inc sales and marketing update

GenomeDx said U.S. healthcare PPO network Prime Health Services Inc. will cover GenomeDx’s Decipher Prostate Cancer Classifier. GenomeDx markets Decipher -- an assay that measures expression levels of 22 undisclosed biomarkers that are correlated with...
07:00 , Oct 31, 2013 |  BC Innovations  |  Distillery Therapeutics

Indication: Cancer

Indication Target/marker/pathway Summary Licensing status Publication and contact information Cancer Prostate cancer Second chromosome locus associated with prostate-1 (SChLAP1; LINC00913) Cell culture and mouse studies suggest inhibiting the long noncoding RNA (lncRNA) SChLAP1 could help...
07:00 , Oct 7, 2013 |  BC Week In Review  |  Financial News

GenomeDx Biosciences completes venture financing

GenomeDx Biosciences Inc. , Vancouver, B.C.   Business: Diagnostic   Date completed: 9/30/13   Type: Venture financing   Raised: Not disclosed   Investors: Merck Global Health Innovation Fund; Baird Venture Partners; Aeris Capital AG; CD...
07:00 , Oct 7, 2013 |  BioCentury  |  Finance

Deciphering GenomeDx

Deciphering GenomeDx While some investors are fleeing the diagnostic space, a series B round for GenomeDx Biosciences Inc. shows there is money out there for companies with a path to reimbursement. The size of the...
00:47 , Oct 1, 2013 |  BC Extra  |  Financial News

GenomeDx closes series B round

Molecular diagnostic company GenomeDx Biosciences Inc. (Vancouver, B.C.) raised an undisclosed amount in a series B round led by new investor Merck Global Health Innovation Fund and a new undisclosed investor. Existing investors Baird Venture...
07:00 , May 6, 2013 |  BC Week In Review  |  Company News

GenomeDx Biosciences, Mayo Clinic deal

The partners expanded a 2009 deal to give GenomeDx exclusive, worldwide rights to develop and commercialize IP developed at the clinic. The deal also includes IP co-developed by the partners and continued access to the...
08:00 , Feb 18, 2013 |  BC Week In Review  |  Clinical News

Decipher test diagnostic data

An analysis of 219 prostate cancer patients who underwent radical prostatectomy showed that GenomeDx Biosciences' Decipher test was a significantly better predictor of prostate cancer metastasis compared to prostate-specific antigen (PSA), tumor stage and grade...